India Pharma Outlook Team | Tuesday, 19 May 2026
Strides Pharma Science Ltd today announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026.
Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex?US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%.”
“Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex?US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth,” he added.
Also Read: Advancing Interventional Radiology in India Through Collaboration
Particulars | Q4FY26 | Q4FY25 | YoY | Q3FY26 | QoQ | FY26 | FY25 | YoY |
Revenue | 13,235 | 11,904 | 11.2% | 11,946 | 10.8% | 48,587 | 45,653 | 6.4% |
Gross Margin | 7,872 | 6,914 | 13.9% | 7,317 | 7.6% | 29,000 | 25,854 | 12.2% |
Gross Margin % | 59.5% | 58.1% | 140bps | 61.2% | -170bps | 59.7% | 56.6% | 310bps |
EBITDA | 2,397 | 2,179 | 10.0% | 2,359 | 1.6% | 9,253 | 8,208 | 15.3% |
EBITDA % | 18.1% | 18.3% | -20bps | 19.8% | -170bps | 19.0% | 17.6% | 140bps |
Operational PAT | 1,357 | 1,130 | 20.0% | 1,282 | 5.9% | 5,181 | 3,447 | 50.3% |
Operational EPS (INR ) | 14.7 | 12.3 | 20.0% | 13.9 | 5.8% | 56.2 | 37.5 | 50.1% |
Reported PAT | 1,293 | 856 | 51.0% | 2,081 | -37.9% | 5,745 | 4,094 | 40.3% |
Reported EPS (INR ) | 13.8 | 8.9 | 54.3% | 21.9 | -37.2% | 60.3 | 44.0 | 37.0% |
Reported PAT = PAT from continuing operations; Operational PAT = Reported PAT excluding exceptional items and one time income
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.
.jpg)
.jpg)
